BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37615532)

  • 1. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with HER2 exon 20 insertion mutation: a case report.
    He X; Hou L; Bai J; Sun C; Wang D; An G
    Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I
    Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab Deruxtecan in
    Li BT; Smit EF; Goto Y; Nakagawa K; Udagawa H; Mazières J; Nagasaka M; Bazhenova L; Saltos AN; Felip E; Pacheco JM; Pérol M; Paz-Ares L; Saxena K; Shiga R; Cheng Y; Acharyya S; Vitazka P; Shahidi J; Planchard D; Jänne PA;
    N Engl J Med; 2022 Jan; 386(3):241-251. PubMed ID: 34534430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic
    Yun KM; Bazhenova L
    BMJ Case Rep; 2023 May; 16(5):. PubMed ID: 37156567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.
    Cancer Discov; 2022 Oct; 12(10):2224. PubMed ID: 35984233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Genomic Features of
    Tan AC; Saw SPL; Chen J; Lai GGY; Oo HN; Takano A; Lau DPX; Yeong JPS; Tan GS; Lim KH; Skanderup AJ; Chan JWK; Teh YL; Rajasekaran T; Jain A; Tan WL; Ng QS; Kanesvaran R; Lim WT; Ang MK; Tan DSW
    JCO Precis Oncol; 2022 Oct; 6():e2200278. PubMed ID: 36240473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond.
    Perez J; Garrigós L; Gion M; Jänne PA; Shitara K; Siena S; Cortés J
    Expert Opin Biol Ther; 2021 Jul; 21(7):811-824. PubMed ID: 33759669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors.
    Indini A; Rijavec E; Grossi F
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
    Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
    J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring
    Kato Y; Kato Y; Minegishi Y; Suzuki T; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Kubota K; Terasaki Y; Seike M; Gemma A
    Onco Targets Ther; 2021; 14():5315-5319. PubMed ID: 34848974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of Tumor Biomarkers from very High to Normal and Extensive Metastatic Lesions to Undetectability in a Patient With Stage IV HER2-positive Breast Cancer Treated With Low-dose Trastuzumab Deruxtecan in Combination With Oral Recombinant Methioninase and a Low-methionine Diet.
    Sato M; Han Q; Mori R; Mizuta K; Kang BM; Morinaga S; Kobayashi N; Ichikawa Y; Nakajima A; Hoffman RM
    Anticancer Res; 2024 Apr; 44(4):1499-1504. PubMed ID: 38538002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab Deruxtecan in Patients With
    Goto K; Goto Y; Kubo T; Ninomiya K; Kim SW; Planchard D; Ahn MJ; Smit EF; de Langen AJ; Pérol M; Pons-Tostivint E; Novello S; Hayashi H; Shimizu J; Kim DW; Kuo CH; Yang JC; Pereira K; Cheng FC; Taguchi A; Cheng Y; Feng W; Tsuchihashi Z; Jänne PA
    J Clin Oncol; 2023 Nov; 41(31):4852-4863. PubMed ID: 37694347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Non-Small Cell Lung Cancer with HER2 Alterations].
    Takakura T; Yamamoto N
    Gan To Kagaku Ryoho; 2023 Jul; 50(7):768-772. PubMed ID: 37496218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting HER2 May Overtake Chemo, Immunotherapy in NSCLC.
    Cancer Discov; 2021 Dec; 11(12):OF3. PubMed ID: 34675060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
    Aoki M; Iwasa S; Boku N
    Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab deruxtecan shows durable activity in HER2-mutant non-small cell lung cancer.
    O'Rourke K
    Cancer; 2022 Mar; 128(5):938. PubMed ID: 35147987
    [No Abstract]   [Full Text] [Related]  

  • 17. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
    Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
    J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
    Tsurutani J; Iwata H; Krop I; Jänne PA; Doi T; Takahashi S; Park H; Redfern C; Tamura K; Wise-Draper TM; Saito K; Sugihara M; Singh J; Jikoh T; Gallant G; Li BT
    Cancer Discov; 2020 May; 10(5):688-701. PubMed ID: 32213540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Potential of Trastuzumab Deruxtecan as a Tissue Agnostic Drug.
    Jørgensen JT
    Oncology; 2023; 101(12):836-842. PubMed ID: 37651992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of HER2 alterations in non-small cell lung cancer - The past, present, and future.
    Nützinger J; Bum Lee J; Li Low J; Ling Chia P; Talisa Wijaya S; Chul Cho B; Min Lim S; Soo RA
    Lung Cancer; 2023 Dec; 186():107385. PubMed ID: 37813015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.